NEW YORK, March 27 - In an effort to develop its protein biochips, Zyomyx said Tuesday it has licensed phage display antibody technology from Dyax.
The agreement is the second antibody collaboration for Zyomyx, which first teamed up with Cambridge Antibody Technology (CAT) last December for access to antibodies in CAT's phage display libraries.